Scarica l'app Stockscreener
7.06
1.53%
-0.11
Precedente Chiudi:
$7.17
Aprire:
$7.16
Volume 24 ore:
428.00K
Relative Volume:
1.13
Capitalizzazione di mercato:
$166.55M
Reddito:
-
Utile/perdita netta:
$-52.07M
Rapporto P/E:
-33.99
EPS:
-0.2077
Flusso di cassa netto:
$-44.93M
1 W Prestazione:
-5.23%
1M Prestazione:
-5.36%
6M Prestazione:
-25.92%
1 anno Prestazione:
-29.78%
Intervallo 1D:
$6.99
$7.23
Intervallo di 1 settimana:
$6.99
$7.75
Portata 52W:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Nome
Cybin Inc
Settore
Industria
Telefono
908 764 8385
Indirizzo
100 King Street West, Suite 5600, Toronto
Confronta CYBN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.06 | 169.14M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Guggenheim | Buy |
| 2021-11-19 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Borsa (CYBN) Ultime notizie
Cybin Posts Q1 2026 Loss of -$0.54 EPS; Market Reacts with Mixed Short-Term Optimism - AInvest
Heatmap Data Shows High Activity in Cybin Inc. SectorRisk Management & Free Weekly Watchlist of Top Performers - newsyoung.net
Cybin Earnings Report (2026 Q1): Negative Net Income, Weak Margins, and Mixed Post-Earnings Market Signals - AInvest
Top Risks to Consider Before Buying Cybin Inc. StockBond Market & Real-Time Market Sentiment Alerts - Newser
Risk adjusted return profile for Cybin Inc. analyzedJuly 2025 Closing Moves & Fast Gain Stock Trading Tips - Newser
Cybin Inc. stock momentum explained2025 Support & Resistance & Consistent Profit Alerts - Newser
Does Cybin Inc. fit your quant trading modelWall Street Watch & Verified Momentum Stock Ideas - Newser
Cybin Inc. recovery potential after sell offInsider Selling & Reliable Breakout Forecasts - Newser
Earnings visualization tools for Cybin Inc.Weekly Stock Summary & Weekly High Potential Alerts - Newser
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin Inc. Reports Q2 2025 Financial Results with Asset Growth - MSN
Real time social sentiment graph for Cybin Inc.2025 Price Targets & Advanced Swing Trade Entry Alerts - Newser
What’s next for Cybin Inc. stock priceQuarterly Earnings Report & Expert Curated Trade Ideas - Newser
Key resistance and support levels for Cybin Inc.Portfolio Update Summary & Safe Capital Investment Plans - Newser
Cybin reports Q1 results - MSN
Is Cybin Inc. stock overvalued or fairly pricedBreakout Watch & Reliable Price Breakout Signals - newsyoung.net
Psychedelic Stock Earnings: atai Life Sciences, Cybin Report Q1 Results - AInvest
Which companies are leading the development of psychedelic wellness products? - AInvest
Cybin Inc. Common Shares (NYSE:CYBN) Stock Quote - FinancialContent
Trend Reversal Possible in Cybin Inc. Charts IndicateWeekly Investment Summary & Fast Entry and Exit Trade Plans - sundaytimes.kr
Psychedelic: atai Life Sciences, Cybin report earnings results - TipRanks
MACD Cross Could Confirm Trend in Cybin Inc.2025 Technical Overview & AI Forecast for Swing Trade Picks - thegnnews.com
Cybin Reports Q1 FY26 Financials, Advances Clinical Programs, and Secures $50M Financing Agreement. - AInvest
Cybin Reports Important Progress on Key Milestones and First Qua - GuruFocus
Cybin Reports Q1 FY26 Financial Results, Advances Key Milestones in Psychedelic Therapies - AInvest
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results - Bluefield Daily Telegraph
Cybin Inc. Amends Convertible Note Agreement with High Trail - TipRanks
Cybin (OTCMKTS:CYBN) Shares Down 2.6% – Should You Sell? - Defense World
What momentum shifts mean for Cybin Inc.Swing Entry Insight With Forecast Accuracy - Newser
Cybin gains Irish Medicines Board approval for major depressive disorder trial - Yahoo Finance
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - BioSpace
Cybin Inc. shares rise 1.13% intraday after receiving approval to initiate EMBRACE trial in Europe. - AInvest
Psychedelic: Cybin receives European approval for EMBRACE study - TipRanks
Cybin receives European approval for EMBRACE trial - TipRanks
Cybin Gets European Approval For EMBRACE Study Of CYB003 For Major Depressive Disorder - Nasdaq
Cybin Secures European Approval for EMBRACE Study in Major Depressive Disorder - TipRanks
Cybin Receives European Approval for EMBRACE, a Multinational Ph - GuruFocus
Cybin receives European approval for phase 3 depression drug trial By Investing.com - Investing.com Nigeria
Cybin receives European approval for phase 3 depression drug trial - Investing.com
Cybin Says Received Approval to Initiate Trial for Major Depressive Disorder in 3 Countries - MarketScreener
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference | CYBN Stock News - GuruFocus
Cybin CEO to Speak at Canaccord Genuity Growth Conference - TipRanks
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference - Business Wire
Cybin Inc. Flashes Rebound Signal in Oversold ConditionAI Driven Buy Alert Trade Blueprint Released - beatles.ru
Technical Heatmap Flags Cybin Inc. for WatchStrong Buy With Technical Confidence Supported - metal.it
Is Cybin Inc. the Top Chart Pick This WeekTrend Analysis for Safer Trades Gains Popularity - metal.it
Using data tools to time your Cybin Inc. exitAI Enhanced Strategy for Portfolio Growth - Newser
What are the latest earnings results for Cybin Inc.Achieve rapid wealth accumulation through smart investing - Jammu Links News
Cybin Inc. Stock Analysis and ForecastFree Market Dynamics Reports - Jammu Links News
How volatile is Cybin Inc. stock compared to the marketCapitalize on emerging investment opportunities - Jammu Links News
What institutional investors are buying Cybin Inc. stockCapitalize on market trends before they peak - Jammu Links News
Cybin Inc Azioni (CYBN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Capitalizzazione:
|
Volume (24 ore):